How the TGA Regulates Therapeutic Goods in Australia

The Australian Register of Therapeutic Goods (ARTG)

The ARTG is the central database of therapeutic goods approved for supply in Australia. If a medicine, medical device, or biological product appears on the ARTG as listed or registered, it has met TGA criteria for quality, safety, and efficacy for its intended use.

You can search the ARTG yourself at tga.gov.au. Enter a product name and verify whether it holds registration. The process takes roughly 30 seconds. Most patients are unaware this tool exists, but it is publicly available and free. When someone claims a product is "TGA-approved," you can verify that claim against the register before your next appointment.

One distinction warrants attention here. Registered products undergo the most rigorous evaluation, including assessment of efficacy data. Listed products, such as some sunscreens and vitamins, meet safety and quality criteria but are not evaluated for efficacy to the same standard. The designation "on the ARTG" does not tell the full story. The category of listing determines the depth of evaluation the product received.

Scheduling: What S4 and S8 Mean for Patients

Medications in Australia fall into schedules that determine how they can be supplied. Two schedules are particularly relevant for telehealth patients: Schedule 4 (prescription only) and Schedule 8 (controlled substances).

Schedule 4 indicates the medication requires a prescription from a registered practitioner. It cannot be purchased over the counter. The prescribing practitioner accepts clinical responsibility for that prescribing decision. This category encompasses a broad range of medications used across many conditions.

Schedule 8 applies stricter controls. These are substances with higher potential for misuse or dependence. Prescribing, dispensing, and record-keeping requirements are correspondingly tighter. State and territory health departments impose an additional layer of oversight for S8 prescribing.

The practical significance is straightforward. The schedule determines who can prescribe a medication, through which regulatory pathway, and with what documentation and oversight. A clinic prescribing S4 medications must follow specific regulatory requirements. If those requirements are not being followed, a direct question applies: what regulatory framework, if any, is governing that prescribing?

The Special Access Scheme (SAS)

The SAS enables practitioners to prescribe therapeutic goods not on the ARTG for individual patients, operating through distinct categories.

SAS Category A applies to gravely ill patients where no comparable registered product exists. The practitioner notifies the TGA but does not require prior approval. SAS Category B requires case-by-case TGA approval before prescribing. The practitioner documents why this specific patient requires this specific medication, and the TGA reviews that reasoning. SAS Category C applies to certain lower-risk products where the practitioner submits a notification.

Documentation requirements unify all categories. Each SAS prescription requires recorded clinical reasoning. The TGA retains authority to audit those records at any time. This is not a rubber stamp. It is a traceability system ensuring non-standard prescribing remains justifiable and auditable.

The Authorised Prescriber (AP) Pathway

The TGA grants AP status to practitioners who demonstrate competence to safely prescribe specific therapeutic goods for specific conditions. The practitioner applies, provides evidence of relevant clinical expertise, and obtains endorsement from a specialist college or ethics committee.

Once granted, AP status permits prescribing defined medications to a specified class of patients without individual SAS applications. The practitioner must maintain detailed prescribing records, submit annual reports to the TGA, and accept audit at any time.

AP status communicates something specific: the practitioner voluntarily sought additional regulatory scrutiny, the TGA assessed their competence, and they accepted ongoing oversight obligations. Not every practitioner holds AP status. That distinction is worth understanding.

Why the Pathway Matters to You

If your clinic does not operate through SAS or AP pathways, a practical question follows: where is the medication sourced? What quality controls govern its production? Who documented the prescribing decision, and who can audit it?

These pathways exist so that non-standard medications reach patients through a regulated, traceable chain: practitioner assessment, documented clinical justification, TGA oversight, and dispensing by registered pharmacists. Remove any link and you lose the safety mechanism the system provides.

The same logic applies in research: if you cannot trace your methodology from sample collection through to published result, the finding is unverifiable. In clinical prescribing, traceability from prescribing decision through to dispensed medication makes the process auditable. Auditability is what separates regulated healthcare from unregulated supply.